Study of LY3457263 for type 2 diabetes on semaglutide or tirzepatide
Part of Hormones & metabolism clinical trials.
This study tests if adding LY3457263 helps lower blood sugar in people with type 2 diabetes who are already taking a stable dose of semaglutide or tirzepatide. You will be randomly assigned to get either LY3457263 or a placebo.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have type 2 diabetes.
- Your average blood sugar (A1c) is between 7.5% and 10.5%.
- Your body mass index (BMI) is 27 or higher.
- Your weight has been steady for the last 3 months.
- You are already taking a stable dose of semaglutide (1 or 2 mg) or tirzepatide (5, 7.5, 10, 12.5, or 15 mg) for at least 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how semaglutide (a medication for type 2 diabetes or weight management) affects your heart, kidneys, and overall metabolic health over time. It uses medical records from LMC endocrinology clinics to track real-world outcomes.
This study tests a new medication called AT673 combined with semaglutide (Wegovy) to help people with type 2 diabetes and overweight or obesity lose weight and improve blood sugar. It is for people who have tried diet and exercise to lose weight but haven't had success.
This study tests a new medicine, NNC0662-0419, in people with type 2 diabetes. You must be willing to lose a lot of weight (more than a quarter of your current weight) as part of the study to see if the medicine helps lower blood sugar.
This study tests if starting two newer diabetes drugs (empagliflozin and semaglutide) soon after diagnosis, along with metformin, helps control blood sugar better than metformin alone. It's for people diagnosed with type 2 diabetes in the last two years who are already taking a high dose of metformin.
This trial tests a new medication called PG-102 for people with type 2 diabetes. It compares PG-102 to a placebo (inactive treatment) and semaglutide (a standard diabetes drug) to see if it can help lower blood sugar and potentially help with weight loss.
This trial tests if a new form of semaglutide works as well as the approved drug Ozempic for lowering blood sugar. It's for adults with type 2 diabetes who are already taking metformin and need better sugar control.
Hear when a new Type 2 diabetes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.